LENZ Therapeutics, Inc. (LENZ) Form 8-K — Oct 28, 2026
LENZ Therapeutics reported Q3 2026 product sales of $2.6 million for VIZZ, up approximately 50% over Q2 2026 on more than 38,000 paid prescriptions, with momentum continuing into Q4 on telehealth adoption and a nationwide TV campaign. The company announced a strategic reorganization cutting headcount by roughly 75% to about 40 employees, with an estimated $5 million in one-time charges in Q4 2026 and a targeted reduction of 2027 operating expenses by more than 50% to approximately $70-$75 million. CEO Eef Schimmelpennink will step down effective December 1, 2026, with CFO Dan Chevallard appointed Interim President and CEO; the board emphasized the departure was not due to any disagreement.
Key figures
- Revenue
- 3384000
- Guidance
- 2027 operating expenses targeted at approximately $70-$75 million (excluding stock-based compensation), a reduction of more than 50%
- Cash Position
- 197300000
- Refill rate
- over 60% of ePharmacy patients purchased more than one monthly pack; ~5 packs/year average
- Sga q3 2026
- $35.8 million vs $27.6 million prior year
- Q3 2025 net loss
- $16.7 million
- Interim ceo salary
- $650,000 with $1.5 million equity award
- Unique prescribers
- over 15,000 since launch
- Headcount reduction
- ~75%, to approximately 40 full-time employees
- Q3 product sales net
- $2.6 million, up ~50% over Q2 2026
- Paid prescriptions q3
- over 38,000, up ~51% over Q2 2026
- Restructuring charges
- ~$5 million in Q4 2026
- Ceo separation payment
- $731,400 lump sum plus $309,016.50 bonus payment
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.